The evolution of health care negotiations and the rise of local innovative drugs | year

As 2020 passed, this year's memorabilia of the pharmaceutical industry was dominated by a sudden new crown outbreak, drawing a line under the national health-care negotiations that have boiled over the industry.
the former created a lot of panic, which caught us off guard, and the latter gave us a gradual look at the direction of the health-care catalog.
the approval of innovative drugs to seamlessly dock into health insurance? Prior to the start of the current health care negotiations, representatives of two sessions submitted to the State Health Insurance Administration "on strengthening China's "independent intellectual property rights" innovative drug support proposal."
the proposal, the representative suggested that the National Health Insurance Administration should establish a policy pilot mechanism of "seamless interface between drug approval and health insurance access, market access", optimize the access mechanism for health insurance, and promote rapid access to innovative medicines.
this, the National Health Insurance Administration replied: the health care sector has always attached great importance to innovative drug access to health care.
medical insurance drug catalog adjustment adhere to the "basic" functional positioning, in principle, once a year adjustment, and through negotiations to some of the clinical essential drugs listed in recent years to reduce prices into the catalog.
, the vast majority of drugs supported by "major new drug creation" science and technology have been included in the national drug catalogue.
Next, the Health Insurance Bureau will take into account the needs of insured persons, affordability, health insurance financing capacity and other factors, through rigorous expert review, and gradually the efficacy of the fund can bear the innovative drugs into the scope of health insurance payments.
means that it is unrealistic to include innovative drugs in their entirety, and negotiations remain the only way forward.
, innovative drugs with precise efficacy and affordable prices are preferred, and there may be more opportunities for varieties with "significant new drug creation" to be added.
five years of negotiations, the rise of indigenous innovative drugs began in 2016 with the first batch of national health-care drug negotiations organized by the former National Health and Family Planning Commission, the fifth of which will take place by the end of 2020.
review of the course of negotiations over the years, from which we can also find a microcosm of the rise of local innovative drugs.
2016 negotiations were the first round of national health-care negotiations involving only five varieties, resulting in three, namely GSK's Tynofovester (67 per cent reduction), Beda Pharmaceuticals' ketina tablet Kemina (54 per cent reduction) and AstraZeneone's Giffordinib (55 per cent).
now appears to have local pharmaceutical companies in the negotiations.
fact, Comey had tried water in local health-care negotiations in several provinces and cities before the talks.
2017, the negotiations reached a landmark breakthrough by including, for the first time, clinically necessary, patented and exclusive drugs with precise efficacy in the health insurance list, extending coverage to areas such as cancer, cardiovascular disease, diabetes, rare diseases, mental illness, infectious diseases, and more.
of the 36 drugs agreed upon, although the average 44 per cent decline may not seem like a high, but most imported drugs have been paid below the surrounding international market prices.
addition, the negotiations also fully reflected the importance and support for pharmaceutical innovation, included in the scope of the negotiations of Sidabenamine, Compaxip, Apatinib and other countries major new drug creation special drugs all successful negotiations.
2018 negotiations are a cancer drug franchise, with 17 of the 18 shortlisted varieties successfully entering the catalogue.
among them, the only domestic drugs are Hengrui's Permen winter enzyme and Zhengda sunny aroteni, the other all imported drugs, the payment standard is lower than the surrounding countries or regions on average 36% lower market prices.
, although there are not many domestic drugs, but there are sensational varieties.
, which began patenting compounds in 2007, opened clinical trials in 2011, completed Phase III clinical trials in 2015, and was approved for listing in May 2018.
its market feedback is also very strong, the first day of sales reached 130 million yuan, in August has exceeded 300 million yuan, the release speed exceeded market expectations.
listed less than half a year into the national health insurance directory and helped it a lot, in 2019 the rapid release of sales reached 3 billion yuan.
the most impressive key word in the 2019 negotiations is "soul cut prices", and the tension on the scene of the negotiations that circulated in the video has at one point made off-screen drug companies and investors feel "suffocated."
70 of the 119 finalists were negotiated, with a success rate of just 58.5 per cent, arguably the lowest in history.
, but the success rate aside, the talks are at an all-time high in terms of the number of drugs accessed and the types of drugs covered.
From the focus area, 22 anti-cancer drugs, 14 chronic diseases (including diabetes, hepatitis B, rheumatoid arthritis, etc.), 7 rare disease medications, 5 essential drugs, 4 children's drugs were successfully negotiated.
from the point of view of innovation support, the vast majority of the drugs in this negotiation are new drugs listed in recent years, many of which have just been listed in 2018, 12 major domestic innovative drugs have been negotiated into eight.
say homegrown innovative drugs are the biggest winners in the 2020 health-care negotiations.
In this negotiation, the most concerned is the PD-1 field, from the results, the local PD-1 are talked about, and imported PD-1 are sorry to miss, this is because local enterprises mainly consider the domestic market, can give more competitive prices, and foreign companies also have to worry about the price comparison of drugs in the international market.
addition, nine of the 16 new drugs included this year are produced by local companies.
newly listed domestic innovative drugs such as Nirapali, Zebtini in Baiji Shenzhou, Amethini in Haussen, and Inito Mono-Resistance in Sansheng have all successfully entered health insurance.
can be seen that the evolution of health care negotiations also reflects the rise of local innovative drugs.
breakthrough in the 2020 negotiations, on the whole, the 2020 negotiations appear to have a much less "tragic" atmosphere, with a higher success rate and a less "frightening" average drop.
health insurance said that it will not deliberately pursue the decline and success rate, only the pursuit of reasonable prices, do not encourage enterprises to inflate pricing, the high success rate is mainly due to the negotiations with the full communication with enterprises.
, there have been many breakthroughs in the negotiations, from form to content.
is the innovation of the finalists.
The past has been nominated and voted by clinical experts, enterprises do not have the qualifications to declare their own, if randomly selected experts are not familiar with the field of treatment, may lead to the species does not have the opportunity to participate in negotiations, which is prone to rare diseases.
Second, the scope of the drug catalog adjustment is set at August 17, 2020 (inclusive) approved for the market by the end of the previous year, which also significantly shortens the waiting period for innovative drugs to enter the health insurance catalog.
is the first attempt to negotiate price reductions for drugs in the catalogue, with selected varieties taking up more funds, being included without negotiation, being economically uneconforming and with alternative drugs on the market.
shows that medicines in the original catalogue are not safe and need to be improved in terms of economy, and this will continue in the future.
In addition, in terms of the therapeutic areas of the negotiated drugs, the negotiation covered the widest range of diseases, including rare disease drugs, children's medications, antidepressants and other 31 clinical groups, accounting for 86% of all clinical groups, which greatly improved the benefits of patients.
And because of this year's outbreak, the Health Insurance Bureau also libawelin injections, Abidor particles and other drugs into the catalog, so far, the latest version of the national new crown pneumonia diagnosis and treatment program listed drugs have been fully included in the national health insurance directory.
, while the agency has said that encouraging innovation is not the job of the agency, health care is the same as businesses, and it's all about patients, supporting and respecting innovations that meet the urgent needs of patients.